(24/7 MARKET NEWS) – Marker Therapeutics, Inc. (NASDAQ: MRKR) reported, this morning, pre-clinical data from the Company’s multiple tumor-associated antigens (multiTAA)-specific T cell product candidate MT-601 in lymphoma cells, including CD19 CAR T refractory cells. Highlights included that, in this in vitro model, 98% of lymphoma cells were eliminated after initial administration of a CD19-targeting CAR T cell product.
Marker Therapeutics is trading at $1.64, up $0.3201 (+23.32%), on 999.26K premarket shares traded.
Its 52-week range is $0.6706 to $6.60. Its next key inflection point is $1.75. If it can break through that resistance on strong trading volume, this may be off to the races.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
